Artralgia of the jaw joint
Conditions
Interventions
Trade Name: Depo-Medrol 40 mg/ml injektionsvätska, suspension
Pharmaceutical Form: Suspension for injection
Pharmaceutical form of the placebo: Solution for injection
Route of administration of the pl
Sponsors
Specialisttandvårdskliniken Västmanlands sjukhus Västerås
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: age 18 or above the diagnosis artralgia in one jaw joint understands Swedish verbally and in written signed informed concent Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 50 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 14
Exclusion criteria
Exclusion criteria: noise from affekted joint( clicking or crepitation) polyarthitis/connective tissue disease bilateral artralgia of jaw joint fibromylagia or other generalized pain ongoing virus or bacterial infection ongoing major restaurations in the mouth corticosteroid injection in affekted jaw joint past 6 months previous sugical intervention of affected jaw joint complex psychiatric or psychological condition hypersensitive to local anesthetics hypersensitive to metylprednisolone hemofilia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Secondary Objective: The secondary objectivs are to evaluate the relief of jaw pain at rest, mouth opening, jaw function, the consequences of pain and the emotional influence following the treatment. Also the variability of pain 3 days before and 5 days after the treatment as well as during 3 days before end of a one month evaluation period is tracked.;Primary end point(s): The differnce in VAS-rated pain intensity at maximal mouth opening from baseline to end of study;Timepoint(s) of evaluation of this end point: After a month;Main Objective: The primary objective is to evaluate the relief of pain at maximal mouth opening following a single dose intra-articular metylprednisolon (Depo-Medrol®) vs. placebo in patients with artralgia of the temporomandibular joint | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): The differnce in VAS-rated pain intensity at jaw rest from baseline to end of study Maximal opening without pain Maximal opening with pain Maximal assisted mouth opening Instruments JFLS GCPS PHQ-9 PGIC;Timepoint(s) of evaluation of this end point: After a month | — |
Countries
Sweden
Contacts
Public ContactGöran Isacsson
Specialisttandvårdskliniken Västmanlands sjukhus Västerås
Outcome results
None listed